Summary:
This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Criteria:- Willing and able to provide written informed consent to participate in the study
- Males and females, aged 18 to 65 years
- In generally good physical health
- Body mass index (BMI) must be between 18 and 40 kg/m2
- Females of reproductive potential and males with partners of reproductive potential must agree to remain abstinent or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug
- Subjects must meet criteria for moderate to severe Major Depressive Disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI)
- Willing and able to comply with the study design schedule and other requirements
Qualified Participants May Receive:
Monetary compensation for participating